Lei Zhou
Research Subjects
Lei Zhou has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Changyong Yang
Jiangsu Hengrui Pharmaceuticals Co. Ltd, Lianyungang, China
17 shared publications - Cheng Liao
Department of Preclinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd , Lianyungang, Jiangsu 222047
17 shared publications - Jiayi Li
State Key Laboratory of Microbial Metabolism Joint International Research Laboratory of Metabolic & Developmental Sciences School of Life Sciences & Biotechnology Shanghai Jiao Tong University Shanghai People's Republic of China
17 shared publications - Jieqiong Zhang
Jiangsu Hengrui Pharmaceuticals Co. Ltd, Lianyungang, China
17 shared publications - Li-Min Wang
Jiangsu Hengrui Pharmaceuticals Co., Ltd , Jiangsu 222047
17 shared publications - Tingting Wu
Shanghai Shengdi Pharmaceutical Co., Ltd., Shanghai, China
17 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
CD40 expression in normal human and rhesus tissues by immunohistochemistry.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
CD40 expression in normal human and rhesus tissues by immunohistochemistry.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding ability of 9E5 to TNF family members.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding ability of 9E5 to TNF family members.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The difference in the binding affinity of SHR-2005 to human and mouse FcgRIIb.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The difference in the binding affinity of SHR-2005 to human and mouse FcgRIIb.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Primary toxicokinetic parameters in rhesus after 4-week repeated administration of SHR-2005.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Primary toxicokinetic parameters in rhesus after 4-week repeated administration of SHR-2005.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Binding of SHR-2005 and APX005M analogue to CD40 from different species as determined by SPR assay.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Binding of SHR-2005 and APX005M analogue to CD40 from different species as determined by SPR assay.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding affinity of 9E5 to human FcgR as determined by SPR assay.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding affinity of 9E5 to human FcgR as determined by SPR assay.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding affinity and predicted binding mode of SHR-2005 to CD40.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding affinity and predicted binding mode of SHR-2005 to CD40.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Effects of SHR-2005 on the release of various cytokines in human peripheral blood mononuclear cells (PBMC).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Effects of SHR-2005 on the release of various cytokines in human peripheral blood mononuclear cells (PBMC).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Anti-tumor activity of SHR-2005-mIgG1 in vivo.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Anti-tumor activity of SHR-2005-mIgG1 in vivo.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Activation of CD40, a pivotal component of immune oncology, could facilitate the infiltration of immune cells into the tumor microenvironment. In this investigation, we characterized SHR-2005, a second-generation CD40 agonistic mAb, as a potential candidate for cancer immune therapy. Our results showed that SHR-2005 possessed high affinity in binding to both human and rhesus CD40 and could effectively compete with CD40L for CD40 binding. Notably, SHR-2005 was engineered to exert a strong affinity for human FcγRIIb, consistent with its observed Fc receptor–dependent agonistic activity. Treatment with SHR-2005 led to robust activation of the CD40 signaling pathway and subsequent immune response. The murine surrogate SHR-2005–mIgG1 exhibited potent inhibition of tumor growth in the MC38 allograft model and showed enhanced antitumor efficacy in combination with the anti–PD-L1 antibody. Furthermore, intravesical instillation of SHR-2005–mIgG1 also increased the populations of dendritic cells (DC), CD3+ T cells, and CD4+ T cells in bladder tissue. No obvious abnormality except for a reversible local irritation was observed via intravesical instillation. Notably, SHR-2005 induced significantly lower IL-6 secretion than the APX005M analogue in human peripheral blood mononuclear cells, indicating a favorable safety profile. In conclusion, the CD40 agonistic antibody SHR-2005 was highly reliant on FcγR for agonistic activation and exhibited promising potential for clinical development as monotherapy or in combination with the anti–PD-L1 antibody for the treatment of solid tumors. Based on promising efficacy and tolerance in preclinical studies, SHR-2005 is currently being evaluated in an ongoing phase I clinical trial for the intravesical treatment of high-risk non–muscle-invasive bladder cancer.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Activation of CD40, a pivotal component of immune oncology, could facilitate the infiltration of immune cells into the tumor microenvironment. In this investigation, we characterized SHR-2005, a second-generation CD40 agonistic mAb, as a potential candidate for cancer immune therapy. Our results showed that SHR-2005 possessed high affinity in binding to both human and rhesus CD40 and could effectively compete with CD40L for CD40 binding. Notably, SHR-2005 was engineered to exert a strong affinity for human FcγRIIb, consistent with its observed Fc receptor–dependent agonistic activity. Treatment with SHR-2005 led to robust activation of the CD40 signaling pathway and subsequent immune response. The murine surrogate SHR-2005–mIgG1 exhibited potent inhibition of tumor growth in the MC38 allograft model and showed enhanced antitumor efficacy in combination with the anti–PD-L1 antibody. Furthermore, intravesical instillation of SHR-2005–mIgG1 also increased the populations of dendritic cells (DC), CD3+ T cells, and CD4+ T cells in bladder tissue. No obvious abnormality except for a reversible local irritation was observed via intravesical instillation. Notably, SHR-2005 induced significantly lower IL-6 secretion than the APX005M analogue in human peripheral blood mononuclear cells, indicating a favorable safety profile. In conclusion, the CD40 agonistic antibody SHR-2005 was highly reliant on FcγR for agonistic activation and exhibited promising potential for clinical development as monotherapy or in combination with the anti–PD-L1 antibody for the treatment of solid tumors. Based on promising efficacy and tolerance in preclinical studies, SHR-2005 is currently being evaluated in an ongoing phase I clinical trial for the intravesical treatment of high-risk non–muscle-invasive bladder cancer.